Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound

10/27/2021 | 07:05am EST
A sign stands outside a Bristol Myers Squibb facility in Cambridge

(Reuters) - Bristol Myers Squibb Co on Wednesday said its third-quarter sales rose 10% and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year.

The New York-based drugmaker's revenue for the quarter of $11.6 billion and adjusted profit of $2.00 per share both topped Wall Street estimates of $11.58 billion in sales and $1.92 per share, according to IBES data from Refinitiv.

Bristol Myers raised the low end of its full-year adjusted profit forecast by 5 cents and now expects to earn $7.40 to $7.55 per share.

Bristol Myers had missed analysts' estimates in the first quarter, largely due to a decline in sales of its growth driver, the cancer immunotherapy Opdivo.

Sales growth has since recovered even as the Delta variant of the coronavirus caused a surge in global COVID-19 cases that could have kept people from seeking treatment for other diseases.

"We're seeing good recovery from COVID really across all of our markets," Chris Boerner, Bristol Myers' chief commercialization officer, said in an interview.

"In immuno-oncology, we've seen a gradual recovery in patient volume," he added. "We're still about 5 to 10% below where we were pre-COVID, but the trend is moving in the right direction."

Cancer drugs Revlimid and Opdivo generated sales of more than $3.3 billion and $1.9 billion respectively. The blood thinner Eliquis, which Bristol shares with Pfizer Inc, brought in more than $2.4 billion. All three were higher than sales reported a year earlier.

The drugmaker is continuing to look at expanding its pipeline of medicines in development through deals, mostly involving smaller, early-stage companies in areas such as cancer, immunology, and cardiovascular health, Chief Financial Officer David Elkins said.

Bloomberg News reported last week that Bristol Myers has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals Inc, citing people familiar with the matter.

(Reporting by Carl O'Donnell; Editing by Bill Berkrot)

By Carl O'Donnell

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AURINIA PHARMACEUTICALS INC. -7.30% 18.67 Delayed Quote.35.00%
BRISTOL-MYERS SQUIBB COMPANY 1.64% 56.32 Delayed Quote.-9.21%
PFIZER, INC. 2.32% 54.27 Delayed Quote.44.09%
S&P 500 -0.84% 4538.43 Delayed Quote.20.15%
Latest news "Economy & Forex"
05:13pBitcoin falls 9.2% to $48,782
05:05pBitcoin falls 9.2% to $48,782
05:00pBitcoin last down 9.3% at $48,773.32; ether last down 3.7% at $4,067.32
04:44pU.s. cdc reports total deaths of 784,893 due to coronavirus as of yesterday vs 783,215 in previous report on dec 3
04:44pU.S. CDC Reports Total Novel Coronavirus Cases Of 48,918,251 As Of Yesterday
04:44pU.s. cdc reports total novel coronavirus cases of 48,918,251 as of yesterday vs 48,767,329 in previous report on dec 3
04:24pTrump's social media venture says it has raised $1 billion
04:19pSudan's Burhan says military will exit politics after 2023 elections
04:12pU.s. cdc says as of dec 4, 45,288,817 people received a booster dose for covid-19 vaccine since august 13, 2021
04:11pU.s. cdc says 198,592,167 individuals have been fully vaccinated against covid-19 as of dec 4 vs 198,211,641 individuals as of dec 3
Latest news "Economy & Forex"